556 related articles for article (PubMed ID: 21551365)
1. Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer.
Krempski J; Karyampudi L; Behrens MD; Erskine CL; Hartmann L; Dong H; Goode EL; Kalli KR; Knutson KL
J Immunol; 2011 Jun; 186(12):6905-13. PubMed ID: 21551365
[TBL] [Abstract][Full Text] [Related]
2. B7-H1 on myeloid-derived suppressor cells in immune suppression by a mouse model of ovarian cancer.
Liu Y; Zeng B; Zhang Z; Zhang Y; Yang R
Clin Immunol; 2008 Dec; 129(3):471-81. PubMed ID: 18790673
[TBL] [Abstract][Full Text] [Related]
3. Increased B7-H1 expression on dendritic cells correlates with programmed death 1 expression on T cells in simian immunodeficiency virus-infected macaques and may contribute to T cell dysfunction and disease progression.
Xu H; Wang X; Pahar B; Moroney-Rasmussen T; Alvarez X; Lackner AA; Veazey RS
J Immunol; 2010 Dec; 185(12):7340-8. PubMed ID: 21059890
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.
Duraiswamy J; Freeman GJ; Coukos G
Cancer Res; 2013 Dec; 73(23):6900-12. PubMed ID: 23975756
[TBL] [Abstract][Full Text] [Related]
5. Expression of programmed death 1 ligands by murine T cells and APC.
Yamazaki T; Akiba H; Iwai H; Matsuda H; Aoki M; Tanno Y; Shin T; Tsuchiya H; Pardoll DM; Okumura K; Azuma M; Yagita H
J Immunol; 2002 Nov; 169(10):5538-45. PubMed ID: 12421930
[TBL] [Abstract][Full Text] [Related]
6. In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.
Oba T; Makino K; Kajihara R; Yokoi T; Araki R; Abe M; Minderman H; Chang AE; Odunsi K; Ito F
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34049930
[TBL] [Abstract][Full Text] [Related]
7. Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma.
Karim R; Jordanova ES; Piersma SJ; Kenter GG; Chen L; Boer JM; Melief CJ; van der Burg SH
Clin Cancer Res; 2009 Oct; 15(20):6341-7. PubMed ID: 19825956
[TBL] [Abstract][Full Text] [Related]
8. Blockade of B7-H1 or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model.
Okudaira K; Hokari R; Tsuzuki Y; Okada Y; Komoto S; Watanabe C; Kurihara C; Kawaguchi A; Nagao S; Azuma M; Yagita H; Miura S
Int J Oncol; 2009 Oct; 35(4):741-9. PubMed ID: 19724910
[TBL] [Abstract][Full Text] [Related]
9. Tumor-induced immune suppression of in vivo effector T-cell priming is mediated by the B7-H1/PD-1 axis and transforming growth factor beta.
Wei S; Shreiner AB; Takeshita N; Chen L; Zou W; Chang AE
Cancer Res; 2008 Jul; 68(13):5432-8. PubMed ID: 18593946
[TBL] [Abstract][Full Text] [Related]
10. Blockage of immune checkpoint molecules increases T-cell priming potential of dendritic cell vaccine.
Hassannia H; Ghasemi Chaleshtari M; Atyabi F; Nosouhian M; Masjedi A; Hojjat-Farsangi M; Namdar A; Azizi G; Mohammadi H; Ghalamfarsa G; Sabz G; Hasanzadeh S; Yousefi M; Jadidi-Niaragh F
Immunology; 2020 Jan; 159(1):75-87. PubMed ID: 31587253
[TBL] [Abstract][Full Text] [Related]
11. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
[TBL] [Abstract][Full Text] [Related]
12. Blockade of B7-H1 suppresses the development of chronic intestinal inflammation.
Kanai T; Totsuka T; Uraushihara K; Makita S; Nakamura T; Koganei K; Fukushima T; Akiba H; Yagita H; Okumura K; Machida U; Iwai H; Azuma M; Chen L; Watanabe M
J Immunol; 2003 Oct; 171(8):4156-63. PubMed ID: 14530338
[TBL] [Abstract][Full Text] [Related]
13. B7-H1-induced apoptosis as a mechanism of immune privilege of corneal allografts.
Hori J; Wang M; Miyashita M; Tanemoto K; Takahashi H; Takemori T; Okumura K; Yagita H; Azuma M
J Immunol; 2006 Nov; 177(9):5928-35. PubMed ID: 17056517
[TBL] [Abstract][Full Text] [Related]
14. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine.
Rosenblatt J; Glotzbecker B; Mills H; Vasir B; Tzachanis D; Levine JD; Joyce RM; Wellenstein K; Keefe W; Schickler M; Rotem-Yehudar R; Kufe D; Avigan D
J Immunother; 2011 Jun; 34(5):409-18. PubMed ID: 21577144
[TBL] [Abstract][Full Text] [Related]
15. Crucial roles of B7-H1 and B7-DC expressed on mesenteric lymph node dendritic cells in the generation of antigen-specific CD4+Foxp3+ regulatory T cells in the establishment of oral tolerance.
Fukaya T; Takagi H; Sato Y; Sato K; Eizumi K; Taya H; Shin T; Chen L; Dong C; Azuma M; Yagita H; Malissen B; Sato K
Blood; 2010 Sep; 116(13):2266-76. PubMed ID: 20574047
[TBL] [Abstract][Full Text] [Related]
16. Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions.
Wu K; Kryczek I; Chen L; Zou W; Welling TH
Cancer Res; 2009 Oct; 69(20):8067-75. PubMed ID: 19826049
[TBL] [Abstract][Full Text] [Related]
17. Phagocytosis, a potential mechanism for myeloid-derived suppressor cell regulation of CD8+ T cell function mediated through programmed cell death-1 and programmed cell death-1 ligand interaction.
Kim YJ; Park SJ; Broxmeyer HE
J Immunol; 2011 Sep; 187(5):2291-301. PubMed ID: 21795591
[TBL] [Abstract][Full Text] [Related]
18. The ability of two Listeria monocytogenes vaccines targeting human papillomavirus-16 E7 to induce an antitumor response correlates with myeloid dendritic cell function.
Peng X; Hussain SF; Paterson Y
J Immunol; 2004 May; 172(10):6030-8. PubMed ID: 15128786
[TBL] [Abstract][Full Text] [Related]
19. Accumulation of memory precursor CD8 T cells in regressing tumors following combination therapy with vaccine and anti-PD-1 antibody.
Karyampudi L; Lamichhane P; Scheid AD; Kalli KR; Shreeder B; Krempski JW; Behrens MD; Knutson KL
Cancer Res; 2014 Jun; 74(11):2974-85. PubMed ID: 24728077
[TBL] [Abstract][Full Text] [Related]
20. Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity.
Cubillos-Ruiz JR; Engle X; Scarlett UK; Martinez D; Barber A; Elgueta R; Wang L; Nesbeth Y; Durant Y; Gewirtz AT; Sentman CL; Kedl R; Conejo-Garcia JR
J Clin Invest; 2009 Aug; 119(8):2231-44. PubMed ID: 19620771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
